Endocrine System Home > Alogliptin

Important Information for Your Healthcare Provider

You should talk with your healthcare provider prior to taking this medication if you have:
  • Liver disease, such as hepatitis, cirrhosis, or liver failure
  • Kidney disease, such as kidney failure (renal failure)
  • Had pancreatitis (inflammation of the pancreas)
  • Gallstones (stones in your gallbladder)
  • A history of alcoholism
  • Any allergies, including to foods, dyes, or preservatives.
Also, let your healthcare provider know if you are:
Make sure to tell your healthcare provider about all other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.
(Click Precautions and Warnings With Alogliptin to learn more, including information on who should not take the drug.)

Clinical Effects of Alogliptin

Alogliptin has been studied alone and in combination with certain other diabetes medicines, including metformin (Glucophage®), sulfonylureas, thiazolidinediones, and insulin. In these studies, the drug was shown to reduce hemoglobin A1c (HbA1c) and fasting blood glucose in people with type 2 diabetes.
Alogliptin Effects on Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. People without diabetes and those who have well-controlled diabetes usually have HbA1c results that are less than 6 percent. Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes, such as heart, eye, nerve, and kidney problems.
In one study, people taking alogliptin for 26 weeks lowered their HbA1c by 0.6 percent on average, while HbA1c results were unchanged in people taking a placebo (a tablet with no active ingredients). Also, 44 percent of those taking alogliptin achieved an HbA1c of 7 or lower after 26 weeks of taking alogliptin, compared with only 23 percent of people taking the placebo.
Alogliptin and Blood Sugar Levels
In studies, people given alogliptin had a 16 mg/dL decrease in their fasting blood sugar, on average. In comparison, people given a placebo had an 11 mg/dL increase in their fasting blood sugar, on average. 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.